Cargando…
Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
Cancer-specific drug delivery represents an attractive approach to preventing undesirable side effects and increasing the accumulation of the drug in tumors. The surface modification of selenium nanoparticles (SeNPs) with targeting moieties thus represents an effective strategy for cancer therapy. I...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274826/ https://www.ncbi.nlm.nih.gov/pubmed/30428576 http://dx.doi.org/10.3390/ijms19113582 |
_version_ | 1783377697331740672 |
---|---|
author | Xia, Yu Xu, Tiantian Zhao, Mingqi Hua, Liang Chen, Yi Wang, Changbing Tang, Ying Zhu, Bing |
author_facet | Xia, Yu Xu, Tiantian Zhao, Mingqi Hua, Liang Chen, Yi Wang, Changbing Tang, Ying Zhu, Bing |
author_sort | Xia, Yu |
collection | PubMed |
description | Cancer-specific drug delivery represents an attractive approach to preventing undesirable side effects and increasing the accumulation of the drug in tumors. The surface modification of selenium nanoparticles (SeNPs) with targeting moieties thus represents an effective strategy for cancer therapy. In this study, SeNPs were modified with folic acid (FA), whose receptors were overexpressed on the surface of cancer cells, including human cervical carcinoma HeLa cells, to fabricate tumor-targeting delivery carrier FA-SeNPs nanoparticles. Then, the anticancer drug doxorubicin (DOX) was loaded onto the surface of the FA-SeNPs for improving the antitumor efficacy of DOX in human cervical carcinoma therapy. The chemical structure characterization of FA-Se@DOX showed that DOX was successfully loaded to the surface of FA-SeNPs to prepare FA-Se@DOX nanoparticles. FA-Se@DOX exhibited significant cellular uptake in human cervical carcinoma HeLa cells (folate receptor overexpressing cells) in comparison with lung cancer A549 cells (folate receptor deficiency cells), and entered HeLa cells mainly by the clathrin-mediated endocytosis pathway. Compared to free DOX or Se@DOX at the equivalent dose of DOX, FA-Se@DOX showed obvious activity to inhibit HeLa cells’ proliferation and induce the apoptosis of HeLa cells. More importantly, FA-Se@DOX could specifically accumulate in the tumor site, which contributed to the significant antitumor efficacy of FA-Se@DOX in vivo. Taken together, FA-Se@DOX may be one novel promising drug candidate for human cervical carcinoma therapy. |
format | Online Article Text |
id | pubmed-6274826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62748262018-12-15 Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles Xia, Yu Xu, Tiantian Zhao, Mingqi Hua, Liang Chen, Yi Wang, Changbing Tang, Ying Zhu, Bing Int J Mol Sci Article Cancer-specific drug delivery represents an attractive approach to preventing undesirable side effects and increasing the accumulation of the drug in tumors. The surface modification of selenium nanoparticles (SeNPs) with targeting moieties thus represents an effective strategy for cancer therapy. In this study, SeNPs were modified with folic acid (FA), whose receptors were overexpressed on the surface of cancer cells, including human cervical carcinoma HeLa cells, to fabricate tumor-targeting delivery carrier FA-SeNPs nanoparticles. Then, the anticancer drug doxorubicin (DOX) was loaded onto the surface of the FA-SeNPs for improving the antitumor efficacy of DOX in human cervical carcinoma therapy. The chemical structure characterization of FA-Se@DOX showed that DOX was successfully loaded to the surface of FA-SeNPs to prepare FA-Se@DOX nanoparticles. FA-Se@DOX exhibited significant cellular uptake in human cervical carcinoma HeLa cells (folate receptor overexpressing cells) in comparison with lung cancer A549 cells (folate receptor deficiency cells), and entered HeLa cells mainly by the clathrin-mediated endocytosis pathway. Compared to free DOX or Se@DOX at the equivalent dose of DOX, FA-Se@DOX showed obvious activity to inhibit HeLa cells’ proliferation and induce the apoptosis of HeLa cells. More importantly, FA-Se@DOX could specifically accumulate in the tumor site, which contributed to the significant antitumor efficacy of FA-Se@DOX in vivo. Taken together, FA-Se@DOX may be one novel promising drug candidate for human cervical carcinoma therapy. MDPI 2018-11-13 /pmc/articles/PMC6274826/ /pubmed/30428576 http://dx.doi.org/10.3390/ijms19113582 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xia, Yu Xu, Tiantian Zhao, Mingqi Hua, Liang Chen, Yi Wang, Changbing Tang, Ying Zhu, Bing Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles |
title | Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles |
title_full | Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles |
title_fullStr | Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles |
title_full_unstemmed | Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles |
title_short | Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles |
title_sort | delivery of doxorubicin for human cervical carcinoma targeting therapy by folic acid-modified selenium nanoparticles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274826/ https://www.ncbi.nlm.nih.gov/pubmed/30428576 http://dx.doi.org/10.3390/ijms19113582 |
work_keys_str_mv | AT xiayu deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT xutiantian deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT zhaomingqi deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT hualiang deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT chenyi deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT wangchangbing deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT tangying deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles AT zhubing deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles |